Psoriasis, a systemic disease?;Psoriazis sistemik bir hastalık mıdır?

Turk Dermatoloji Dergisi

Volumn 6, Issue 3, 2012, Pages 119-122

  Atakan, Nilgün ^a   Doǧan, Sibel ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Bayrampa a Devlet Hastanesi Psikiyatri Klini i   (Turkey)

Author keywords

Atherosclerosis; Cardiovascular diseases; Chronic inflammation; Comorbidity; Crohn's disease; Metabolic syndrome; Obesity; Psoriasis; Psoriatic arthritis

Indexed keywords

COMORBIDITY; PATHOGENESIS; PSORIASIS; REVIEW;

EID: 84867431685     PISSN: 13077635     EISSN: 13085255     Source Type: Journal    
DOI: 10.5152/tdd.2012.27     Document Type: Review

References (45)

1. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36. [CrossRef]
2. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25:529-34. [CrossRef]
3. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35. [CrossRef]
4. Sweeney CM, Tobin AM, Kirby B. Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res 2011;303:691-705. [CrossRef]
5. Dogan S, Atakan N. Is serum amyloid A protein a better indicator of inflammation in severe psoriasis? Br J Dermatol 2010;163:895-6. [CrossRef]
6. Hoede N, Morsches B, Holzmann H. Psoriasis, a systemic disease. Internist (Berl) 1974;1584:186-91.
7. Guttman-Yassky E, Krueger JG. Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. Br J Dermatol 2007;157:1103-15. [CrossRef]
8. Enno C, Mrowietz U. Psoriasis. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC (eds). Braun-Falco's Dermatology. 3rd ed. Springer, New York. 2009.
9. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54:67-80. [CrossRef]
10. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-70. [CrossRef]
11. Kaur S, Zimmer K, Leping V, Zilmer M. Comparative study of systemic inflammatory responses in psoriasis vulgaris and mild to moderate allergic contact dermatitis. Dermatology Aug 9. [Epub ahead of print]
12. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6. [CrossRef]
13. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-24. [CrossRef]
14. Eaglstein WH, Callen JP. Dermatologic comorbidities of diabetes mellitus and related issues. Arch Dermatol 2009;145;467-9. [CrossRef]
15. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital based case control study. Br J Dermatol 2007;1:68-73. [CrossRef]
16. Nieman AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;10:829-35. [CrossRef]
17. Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006;8:355-63. [CrossRef]
18. Xydakis AM, Case CC, Jones PH. Adiponectin, inflammation and the expression of the metabolic syndrome in obese individuals: The impact of rapid weight loss through caloric restriction. J Clin Endocrin Met 2004;89:2697-703. [CrossRef]
19. Bruun JM, Verdich C, Toubro, et al. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-α. Effect of weight loss in obese men. Eur J Endocrin 2003;148:535-42. [CrossRef]
20. Hamminga EA, Van der Lely AJ, Neumann HAM, Thio HB. Chronic inflammation in psoriasis and obesity: Implications for therapy. Med Hypotheses 2006;67:768-73. [CrossRef]
21. Sterry W, Strober BE, Menter A, et al. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-55. [CrossRef]
22. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8. [CrossRef]
23. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633-6. [CrossRef]
24. Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr 2011;159:577-83. [CrossRef]
25. Au S, Goldminz M, Loo DS, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol 2012;66:1012-3. [CrossRef]
26. Baumann H, Gauldie J. The acute phase response. Immun Today 1994;15:74-80. [CrossRef]
27. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and severe psoriasis. Br J Dermatol 2004;150:917-28. [CrossRef]
28. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99:469-75. [CrossRef]
29. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298-304. [CrossRef]
30. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30. [CrossRef]
31. Friedewald VE, Cather JC, Gordon KB, et al. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol 2008;101:1119-26. [CrossRef]
32. Friedewald VE, Cather JC, Gelfand J, et al. AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. Am J Cardiol 2008;102:1631-43. [CrossRef]
33. Ahlehoff O, Gislason GH, Jørgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012;33:2054-64. [CrossRef]
34. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011;124:775. e1-6.
35. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. [CrossRef]
36. Vanizor Kural B, Orem A, Cimşit G, et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clinica Chim Acta 2003;332:23-30. [CrossRef]
37. Gudjonsson JE, Elder JT. Psoriasis. In: Wolff K, Lowell AG, Stephen I (eds). Fitzpatrick's dermatology in general medicine. 7th ed. McGraw-Hill, NewYork. 2008;169-94.
38. Steel DM, Whitehead AS. The major acute phase reactants: C reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81-8. [CrossRef]
39. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-7. [CrossRef]
40. Kundakçi{dotless} N, Türsen Ü, Babiker MO, Gürgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002;41:220-4. [CrossRef]
41. Leman J, Burden D. Psoriasis in children: a guide to its diagnosis and management. Pediatr Drugs 2001;3:673-80. [CrossRef]
42. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003;48:805-21. [CrossRef]
43. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309-19. [CrossRef]
44. Sugita T. Targeting therapy for inflammatory diseases by anti-TNF-α biologics. Yakugaku Zasshi 2009;129:19-24. [CrossRef]
45. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012;26 (Suppl. 2):3-11. [CrossRef]